Is Weight Gain an Unavoidable Consequence of Insulin Therapy

No abstract is available for this paper.

• Publication year

  2006

• Venue

  The Internet Journal of Internal Medicine

• Publication date

  2006-12-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.5580/1cb5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes

  2007cited by this paper
• Albumin‐bound basal insulin analogues (insulin detemir and NN344): comparable time‐action profiles but less variability than insulin glargine in type 2 diabetes

  2007cited by this paper
• Insights from the diabetes control and complications trial/epidemiology of diabetes interventions and complications study on the use of intensive glycemic treatment to reduce the risk of complications of type 1 diabetes.

  2006cited by this paper
• Tissue selectivity of insulin detemir action in vivo

  2006cited by this paper
• Insulin detemir: a new basal insulin analogue

  2006cited by this paper
• Insulin detemir: from concept to clinical experience

  2006cited by this paper
• Weight gain and insulin treatment.

  2005cited by this paper
• Lower within‐subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

  2005cited by this paper
• Reproducibility and variability in the action of injected insulin.

  2005cited by this paper
• Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes management

  2005cited by this paper
• How to achieve a predictable basal insulin?

  2005cited by this paper
• A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.

  2005cited by this paper
• Initiating basal insulin therapy in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique

  2005cited by this paper
• Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin

  2005cited by this paper
• Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

  2005cited by this paper
• Effects of liraglutide (NN2211), a long‐acting GLP‐1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes

  2005cited by this paper
• Basal insulin therapy in type 2 diabetes.

  2005influential reference
• Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

  2005cited by this paper
• Insulin Detemir—A New Basal Insulin Analog

  2005cited by this paper
• The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

  2004cited by this paper
• Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function.

  2004influential reference
• Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir

  2004cited by this paper
• IN DEVELOPING COUNTRIES : Comparison of “ DAE 642 Adult Education and Development ” and “ BIS 204 Data Organization Methods ” at the University of Botswana

  2004cited by this paper
• At last, a weight neutral insulin?

  2004influential reference
• Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.

  2004cited by this paper
• Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial.

  2004influential reference
• Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial.

  2004cited by this paper
• The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes.

  2004cited by this paper
• Weight gain and insulin therapy

  2004cited by this paper
• Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.

  2004cited by this paper
• Insulin detemir: improving the predictability of glycaemic control

  2004cited by this paper
• Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

  2004cited by this paper
• Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with Type 1 diabetes

  2004influential reference
• Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

  2004influential reference
• Treatment of the patient with diabetes: importance of maintaining target HbA1c levels

  2004cited by this paper
• Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review.

  2003cited by this paper
• Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001.

  2003cited by this paper
• Importance of Weight Management in Type 2 Diabetes: Review with Meta-analysis of Clinical Studies

  2003cited by this paper
• The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

  2003cited by this paper
• The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

  2003cited by this paper
• Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

  2003cited by this paper
• Current therapeutic options in type 2 diabetes mellitus: a practical approach.

  2003cited by this paper
• Medical Management of Type 2 Diabetes

  2003cited by this paper
• Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus.

  2003cited by this paper
• Leptin and insulin action in the central nervous system.

  2002cited by this paper
• A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.

  2002cited by this paper
• Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).

  2002cited by this paper
• Initial Management of Glycemia in Type 2 Diabetes Mellitus

  2002cited by this paper
• Intensive diabetes management

  2002cited by this paper
• New insulins in the treatment of diabetes mellitus.

  2002cited by this paper
• The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: The AACE System of Intensive Diabetes Self-Management - 2002 Update

  2002cited by this paper
• Insulin therapy in type 2 diabetes.

  2001influential reference
• Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

  2001cited by this paper
• Beneficial and Detrimental Effects of Intensive Glycaemic Control, with Emphasis on Type 2 Diabetes Mellitus

  2000cited by this paper
• A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

  2000cited by this paper
• Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

  2000cited by this paper
• Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

  2000cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Central nervous system control of food intake

  2000cited by this paper
• Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens.

  1999cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49)

  1999cited by this paper
• Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus

  1999cited by this paper
• Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• The Prevention and Treatment of Obesity: Application to type 2 diabetes

  1997cited by this paper
• Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus.

  1996cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial

  1993cited by this paper
• Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus.

  1992cited by this paper
• Weight Gain Associated With Improved Glycemic Control in Population-Based Sample of Subjects With Type I Diabetes

  1990cited by this paper
• Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

  1988cited by this paper
• Weight Gain Associated With Intensive Therapy in the Diabetes Control and Complications Trial

  1988cited by this paper
• Insulin exerts metabolic and growth-promoting effects by a direct action on the liver in vivo: clarification of the functional significance of the portal vascular link between the beta cells of the pancreatic islets and the liver.

  1987cited by this paper
• Insulin infusion during a nocturnal fast suppresses the subsequent day-time intake.

  1984cited by this paper
• Is regulation of body weight elucidated.

  1984cited by this paper
• Factors Influencing the Absorption, Serum Insulin Concentration, and Blood Glucose Responses After Injections of Regular Insulin and Various Insulin Mixtures

  1981cited by this paper
• rapid communication Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2

  year unknowncited by this paper

• Hyp-O-besity: Unmet Challenge in Management of Type 2 Diabetes Mellitus and Cardiovascular Risk

  2015cites this paper
• Lessons from DAWN: Implementing Effective Insulin Therapy

  2008cites this paper